Lantern Pharma Advances EMA-Cleared Trial for Biomarker-Selected Bladder Cancer Drug
Event summary
- Lantern Pharma's Phase 1b/2 trial for LP-184 (zirdafulven) in advanced bladder cancer cleared by EMA.
- Trial will be conducted at Rigshospitalet in Copenhagen, led by Professors Kristoffer Staal Rohrberg and Helle Pappot.
- Study uses dual biomarker strategy (PTGR1 overexpression + DNA-damage-repair deficiency) to select patients.
- Primary endpoint is objective response rate (ORR) by RECIST 1.1, with planned enrollment of up to 39 patients.
The big picture
Lantern Pharma's EMA-cleared trial for LP-184 reflects a strategic push toward precision oncology, leveraging AI-driven biomarker selection to target advanced bladder cancer. The study addresses a significant unmet need in the third-line setting, where treatment options are limited and outcomes are poor. With the global metastatic urothelial carcinoma market projected to grow substantially, Lantern's approach could differentiate it from competitors focusing on antibody-drug conjugates or FGFR inhibitors.
What we're watching
- Clinical Efficacy
- Whether LP-184 can demonstrate meaningful objective response rates in biomarker-selected bladder cancer patients.
- Regulatory Pathway
- The pace at which Lantern Pharma advances LP-184 through additional trials and potential approvals beyond this Phase 1b/2 study.
- Commercial Opportunity
- How the dual biomarker strategy positions LP-184 in the competitive landscape of advanced bladder cancer therapies.
Related topics